vs
Envela Corp（ELA）与RIGEL PHARMACEUTICALS INC（RIGL）财务数据对比。点击上方公司名可切换其他公司
Envela Corp的季度营收约是RIGEL PHARMACEUTICALS INC的1.2倍（$80.5M vs $69.8M），RIGEL PHARMACEUTICALS INC净利率更高（384.0% vs 7.4%，领先376.6%），Envela Corp同比增速更快（66.6% vs 21.2%），过去两年RIGEL PHARMACEUTICALS INC的营收复合增速更高（53.7% vs 42.1%）
Envela Corp是一家总部位于美国的企业，核心开展再流通业务，致力于延长产品生命周期、减少资源消耗。公司业务主要分为两大板块，分别面向个人消费者端与企业商业端，通过盘活二手资源实现可持续的商业价值。
Rigel制药是一家临床阶段生物技术企业，专注于研发及商业化针对自身免疫性疾病、炎症性疾病与血液疾病的靶向小分子疗法，核心市场位于美国，旗下已获批产品可治疗成人免疫性血小板减少症，致力于满足未被覆盖的临床医疗需求。
ELA vs RIGL — 直观对比
营收规模更大
ELA
是对方的1.2倍
$69.8M
营收增速更快
ELA
高出45.4%
21.2%
净利率更高
RIGL
高出376.6%
7.4%
两年增速更快
RIGL
近两年复合增速
42.1%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $80.5M | $69.8M |
| 净利润 | $6.0M | $268.1M |
| 毛利率 | 20.5% | 91.5% |
| 营业利润率 | 9.4% | 33.2% |
| 净利率 | 7.4% | 384.0% |
| 营收同比 | 66.6% | 21.2% |
| 净利润同比 | 274.6% | 1769.2% |
| 每股收益（稀释后） | $0.22 | $14.11 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ELARIGL
| Q4 25 | $80.5M | $69.8M | ||
| Q3 25 | $57.4M | $69.5M | ||
| Q2 25 | $54.9M | $101.7M | ||
| Q1 25 | $48.3M | $53.3M | ||
| Q4 24 | $48.3M | $57.6M | ||
| Q3 24 | $46.9M | $55.3M | ||
| Q2 24 | $45.3M | $36.8M | ||
| Q1 24 | $39.9M | $29.5M |
净利润ELARIGL
| Q4 25 | $6.0M | $268.1M | ||
| Q3 25 | $3.4M | $27.9M | ||
| Q2 25 | $2.8M | $59.6M | ||
| Q1 25 | $2.5M | $11.4M | ||
| Q4 24 | $1.6M | $14.3M | ||
| Q3 24 | $1.7M | $12.4M | ||
| Q2 24 | $1.6M | $-1.0M | ||
| Q1 24 | $1.9M | $-8.2M |
毛利率ELARIGL
| Q4 25 | 20.5% | 91.5% | ||
| Q3 25 | 22.8% | 93.2% | ||
| Q2 25 | 22.6% | 95.6% | ||
| Q1 25 | 24.8% | 91.7% | ||
| Q4 24 | 23.1% | 89.9% | ||
| Q3 24 | 24.4% | 85.5% | ||
| Q2 24 | 25.1% | 92.4% | ||
| Q1 24 | 25.9% | 93.1% |
营业利润率ELARIGL
| Q4 25 | 9.4% | 33.2% | ||
| Q3 25 | 7.3% | 40.9% | ||
| Q2 25 | 5.9% | 60.1% | ||
| Q1 25 | 6.5% | 23.9% | ||
| Q4 24 | 3.9% | 28.9% | ||
| Q3 24 | 4.3% | 25.4% | ||
| Q2 24 | 4.2% | 1.2% | ||
| Q1 24 | 5.9% | -23.6% |
净利率ELARIGL
| Q4 25 | 7.4% | 384.0% | ||
| Q3 25 | 5.8% | 40.2% | ||
| Q2 25 | 5.0% | 58.6% | ||
| Q1 25 | 5.2% | 21.5% | ||
| Q4 24 | 3.3% | 24.9% | ||
| Q3 24 | 3.6% | 22.5% | ||
| Q2 24 | 3.5% | -2.8% | ||
| Q1 24 | 4.8% | -27.9% |
每股收益（稀释后）ELARIGL
| Q4 25 | $0.22 | $14.11 | ||
| Q3 25 | $0.13 | $1.46 | ||
| Q2 25 | $0.11 | $3.28 | ||
| Q1 25 | $0.10 | $0.63 | ||
| Q4 24 | $0.07 | $0.82 | ||
| Q3 24 | $0.06 | $0.70 | ||
| Q2 24 | $0.06 | $-0.06 | ||
| Q1 24 | $0.07 | $-0.47 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $155.0M |
| 总债务越低越好 | $9.9M | $52.5M |
| 股东权益账面价值 | $67.1M | $391.5M |
| 总资产 | $96.0M | $513.6M |
| 负债/权益比越低杠杆越低 | 0.15× | 0.13× |
8季度趋势，按日历期对齐
现金及短期投资ELARIGL
| Q4 25 | — | $155.0M | ||
| Q3 25 | — | $137.1M | ||
| Q2 25 | — | $108.4M | ||
| Q1 25 | — | $77.1M | ||
| Q4 24 | — | $77.3M | ||
| Q3 24 | — | $61.1M | ||
| Q2 24 | — | $49.1M | ||
| Q1 24 | $19.8M | $49.5M |
总债务ELARIGL
| Q4 25 | $9.9M | $52.5M | ||
| Q3 25 | $12.5M | $60.0M | ||
| Q2 25 | $13.0M | $60.0M | ||
| Q1 25 | $13.2M | $60.0M | ||
| Q4 24 | $13.5M | $60.0M | ||
| Q3 24 | $13.8M | $60.0M | ||
| Q2 24 | $14.3M | $60.0M | ||
| Q1 24 | $14.6M | $60.0M |
股东权益ELARIGL
| Q4 25 | $67.1M | $391.5M | ||
| Q3 25 | $61.1M | $117.6M | ||
| Q2 25 | $57.8M | $81.9M | ||
| Q1 25 | $55.1M | $18.6M | ||
| Q4 24 | $52.7M | $3.3M | ||
| Q3 24 | $51.1M | $-14.6M | ||
| Q2 24 | $50.2M | $-29.9M | ||
| Q1 24 | $49.3M | $-31.7M |
总资产ELARIGL
| Q4 25 | $96.0M | $513.6M | ||
| Q3 25 | $90.9M | $242.5M | ||
| Q2 25 | $82.7M | $206.7M | ||
| Q1 25 | $79.7M | $176.0M | ||
| Q4 24 | $77.9M | $164.0M | ||
| Q3 24 | $77.4M | $139.4M | ||
| Q2 24 | $73.8M | $128.4M | ||
| Q1 24 | $74.7M | $126.5M |
负债/权益比ELARIGL
| Q4 25 | 0.15× | 0.13× | ||
| Q3 25 | 0.20× | 0.51× | ||
| Q2 25 | 0.23× | 0.73× | ||
| Q1 25 | 0.24× | 3.23× | ||
| Q4 24 | 0.26× | 18.25× | ||
| Q3 24 | 0.27× | — | ||
| Q2 24 | 0.29× | — | ||
| Q1 24 | 0.30× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-3.5M | $22.0M |
| 自由现金流经营现金流 - 资本支出 | $-3.7M | — |
| 自由现金流率自由现金流/营收 | -4.6% | — |
| 资本支出强度资本支出/营收 | 0.2% | — |
| 现金转化率经营现金流/净利润 | -0.59× | 0.08× |
| 过去12个月自由现金流最近4个季度 | $1.4M | — |
8季度趋势，按日历期对齐
经营现金流ELARIGL
| Q4 25 | $-3.5M | $22.0M | ||
| Q3 25 | $2.4M | $24.0M | ||
| Q2 25 | $2.6M | $30.5M | ||
| Q1 25 | $1.1M | $-893.0K | ||
| Q4 24 | $3.7M | $14.5M | ||
| Q3 24 | $3.4M | $21.7M | ||
| Q2 24 | $-789.5K | $302.0K | ||
| Q1 24 | $3.8M | $-5.0M |
自由现金流ELARIGL
| Q4 25 | $-3.7M | — | ||
| Q3 25 | $2.2M | — | ||
| Q2 25 | $2.1M | — | ||
| Q1 25 | $746.6K | — | ||
| Q4 24 | $3.2M | — | ||
| Q3 24 | $1.5M | — | ||
| Q2 24 | $-1.3M | — | ||
| Q1 24 | $3.3M | — |
自由现金流率ELARIGL
| Q4 25 | -4.6% | — | ||
| Q3 25 | 3.8% | — | ||
| Q2 25 | 3.9% | — | ||
| Q1 25 | 1.5% | — | ||
| Q4 24 | 6.7% | — | ||
| Q3 24 | 3.1% | — | ||
| Q2 24 | -2.9% | — | ||
| Q1 24 | 8.4% | — |
资本支出强度ELARIGL
| Q4 25 | 0.2% | — | ||
| Q3 25 | 0.4% | — | ||
| Q2 25 | 0.8% | — | ||
| Q1 25 | 0.8% | — | ||
| Q4 24 | 1.0% | — | ||
| Q3 24 | 4.2% | — | ||
| Q2 24 | 1.1% | — | ||
| Q1 24 | 1.1% | — |
现金转化率ELARIGL
| Q4 25 | -0.59× | 0.08× | ||
| Q3 25 | 0.72× | 0.86× | ||
| Q2 25 | 0.94× | 0.51× | ||
| Q1 25 | 0.45× | -0.08× | ||
| Q4 24 | 2.34× | 1.01× | ||
| Q3 24 | 2.05× | 1.75× | ||
| Q2 24 | -0.50× | — | ||
| Q1 24 | 1.99× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ELA
| Consumer Segment | $67.7M | 84% |
| Commercial Segment | $12.8M | 16% |
RIGL
暂无分部数据
